目的 观察奥扎格雷钠注射液联合长春西汀注射液治疗椎–基底动脉供血不足的临床疗效及安全性。方法 选择2010年1月—2012年11月诸城市人民医院确诊的150例椎–基底动脉供血不足的病人，随机分为治疗组（80例）和对照组（70例），对照组患者给予80 mg奥扎格林钠＋生理盐水250 mL，静脉滴注，2 次/d。治疗组给予30 mg长春西汀＋250 mL生理盐水，静脉滴注，1 次/d，奥扎格林钠的用法及用量同对照组。两组均连续治疗14 d。治疗结束后，观察两组患者的治疗效果、TCD血管流速改变情况以及不良反应发生情况。结果 治疗组和对照组总有效率分别为96.2%、82.8%，两组比较差异有统计学意义（P＜0.05）；治疗组TCD收缩峰流速改善高于对照组，两组比较差异有统计学意义（P＜0.05）。不良反应发生率差异无统计学意义（P＞0.05）。结论 奥扎格雷钠联合长春西汀治疗椎–基底动脉供血不足具有较好疗效，临床应用安全。

Objective To evaluate the clinical efficiency and security of Ozagreiner Injection combined with Vinpocetine Injection (OI-VI) on vertebro-basicarterial ischemia. Methods The patients (150 cases) diagnosed as vertebro-basicarterial ischemia in Zhucheng People’s Hospital from January 2010 to November 2012 were randomly divided into treatment group (80 cases) and control group (70 cases). Patients in the control group were iv administered with OI (80 mg) added into 250 mL physiological saline, twice daily for 14 d. Patients in the treatment group were iv administered with VI (30 mg) added into 250 mL physiological saline, once daily for 14 d, and the usage and dosage of OI were the same as the control group. After treatment, the therapeutic effects, blood flow changes from TCD and adverse reactions were observed. Results The efficiency of the treatment and control groups was 96.2% and 82.8% with the significant difference (P < 0.05). The peak systolic velocity from TCD in the treatment group was higher than that in the control group (P < 0.05), and the adverse reactions between the two groups had no significant difference (P > 0.05). Conclusion The clinical efficacy of OI-VI is better in the treatment of vertebro-basicarterial ischemia and the therapeutic effect is reliable and safe.